News

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update

Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif., August 9, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 … Continued

ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2022 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 19, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2022 … Continued

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update

Conference Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif., May 18, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 … Continued

ThermoGenesis Holdings Announces Year End 2021 Financial Results and Provides Corporate Update

Company Signs License Agreement With Boyalife Genomics and will Form TG Biosynthesis Division to Operate as CDMO for Cell and Cell-Based Gene Therapies RANCHO CORDOVA, Calif., March 28, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial … Continued

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2021 and Provide a Corporate Strategic Update

Conference Call to be Held on March 28, 2022 RANCHO CORDOVA, Calif., March 23, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 … Continued

Thermogenesis Holdings CEO, Dr. Chris Xu, featured in BioPharm International Q&A Article

ThermoGenesis Holdings had the pleasure of having our very own C.E.O., Dr. Chris Xu, featured in a Q&A article by BioPharm International where a panel of experts were asked questions about the growth, challenges & opportunities within the cell & gene therapy industry. We invite you to read the BioPharm international article which can be … Continued

Combining Microbubbles & Cell Sorting for Quick & Efficient Cell Isolation

Preparing cell samples is an essential part of achieving success in cell and gene therapy manufacturing. Achieving high-quality results requires that samples be pure, with high viability and free of any damage caused by harsh retrieval techniques. Current cell isolation techniques can be time-consuming and cause stress to cell samples, which is why there is … Continued

ThermoGenesis Holdings to Hold Reconvened Annual Meeting of Stockholders on January 13, 2022

RANCHO CORDOVA, Calif., January 11, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”) will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST. The meeting, originally scheduled for December 16, 2021, was convened and adjourned without any business being conducted due to … Continued

ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference

RANCHO CORDOVA, Calif., January 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. The … Continued

How may we help?